These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7733838)
21. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226 [TBL] [Abstract][Full Text] [Related]
22. [Buspirone in the treatment of cerebellar ataxia]. Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900 [TBL] [Abstract][Full Text] [Related]
23. [Physostigmine in treatment of cerebellar ataxia]. Aschoff JC; Kailer NA; Walter K Nervenarzt; 1996 Apr; 67(4):311-8. PubMed ID: 8684510 [TBL] [Abstract][Full Text] [Related]
24. The role of buspirone for the treatment of cerebellar ataxia in an older individual. Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493 [TBL] [Abstract][Full Text] [Related]
25. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. Bier JC; Dethy S; Hildebrand J; Jacquy J; Manto M; Martin JJ; Seeldrayers P J Neurol; 2003 Jun; 250(6):693-7. PubMed ID: 12796831 [TBL] [Abstract][Full Text] [Related]
26. Structural and functional MRI abnormalities of cerebellar cortex and nuclei in SCA3, SCA6 and Friedreich's ataxia. Stefanescu MR; Dohnalek M; Maderwald S; Thürling M; Minnerop M; Beck A; Schlamann M; Diedrichsen J; Ladd ME; Timmann D Brain; 2015 May; 138(Pt 5):1182-97. PubMed ID: 25818870 [TBL] [Abstract][Full Text] [Related]
33. Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders. Klein P; Lees A; Stern G Adv Neurol; 1987; 45():603-4. PubMed ID: 3493632 [No Abstract] [Full Text] [Related]
34. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Ristori G; Romano S; Visconti A; Cannoni S; Spadaro M; Frontali M; Pontieri FE; Vanacore N; Salvetti M Neurology; 2010 Mar; 74(10):839-45. PubMed ID: 20211908 [TBL] [Abstract][Full Text] [Related]
35. L-5-hydroxytryptophan for LSD-induced psychosis. Abraham HD Am J Psychiatry; 1983 Apr; 140(4):456-8. PubMed ID: 6601463 [TBL] [Abstract][Full Text] [Related]
36. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Schulte T; Mattern R; Berger K; Szymanski S; Klotz P; Kraus PH; Przuntek H; Schöls L Arch Neurol; 2001 Sep; 58(9):1451-7. PubMed ID: 11559318 [TBL] [Abstract][Full Text] [Related]
37. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Romano S; Coarelli G; Marcotulli C; Leonardi L; Piccolo F; Spadaro M; Frontali M; Ferraldeschi M; Vulpiani MC; Ponzelli F; Salvetti M; Orzi F; Petrucci A; Vanacore N; Casali C; Ristori G Lancet Neurol; 2015 Oct; 14(10):985-91. PubMed ID: 26321318 [TBL] [Abstract][Full Text] [Related]
38. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine]. Maissen CP; Ludin HP Schweiz Med Wochenschr; 1991 Oct; 121(43):1585-90. PubMed ID: 1947955 [TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging in degenerative ataxic disorders. Ormerod IE; Harding AE; Miller DH; Johnson G; MacManus D; du Boulay EP; Kendall BE; Moseley IF; McDonald WI J Neurol Neurosurg Psychiatry; 1994 Jan; 57(1):51-7. PubMed ID: 8301305 [TBL] [Abstract][Full Text] [Related]
40. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. Ceci F; Cangiano C; Cairella M; Cascino A; Del Ben M; Muscaritoli M; Sibilia L; Rossi Fanelli F J Neural Transm; 1989; 76(2):109-17. PubMed ID: 2468734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]